Yesterday Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) issued a rather encouraging PR. The company revealed that their Phase 3 clinical study of Probuphine for Opioid addiction met the pre-specified primary endpoint of non-inferiority in addition to...
Minutes after the opening bell rang signaling the start of yesterday’s trading the stock of Titan Pharmaceuticals, Inc (OTCMKTS:TTNP) slid down in to the red to a low of $0.71 per share. The ticker was...
This week the stock of Titan Pharmaceuticals, Inc (OTCMKTS:TTNP) reached its highest trading price for the last eight months. It seems that such prices may be a bit too much for the stock to handle....
Titan Pharmaceuticals, Inc. (OTCBB:TTNP) had a nice green run from June 11 to June 19, managing to rise all the way up to $0.845 by last Thursday’s closing bell. Unfortunately, the climb’s last jump...
Since June 11 the stock of Titan Pharmaceuticals, Inc. (OTCBB:TTNP) has been going nowhere but up. The daily price gains were not that impressive but nonetheless in just six sessions the stock climbed from...
National Holdings, Corp. (OTCBB:NHLD) with its high price remains an unusual choice for investors, but it invited more attention and higher volumes in the past months. The question is whether the current prices would...
BioMatrix Scientific Group, Inc. (OTCMKTS:BMSN) proved once again that it needs publicity to boost its price growth. After a few subdued weeks, BMSN was bought up again, leading to a price growth of more...
MRI Interventions, Inc. (OTCBB:MRIC) was just drifting at a nice price range when it followed the fate of many biotech tickers- a sudden crash, on what was perceived as disappointing news. MRIC slid down...
Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) acts truly concerned about its future, and luckily, in the past days offered up important corporate updates. At the same time, the stock price still seeks direction. On Monday, the...
MultiCell Technologies, Inc. (OTCMKTS:MCET) is in the sweet spot of most pharmaceutical companies- boosted by enough recent developments, and still interesting enough to investors to support a period of significant price growth. On Monday,...